National Utilization of Calcium Supplements in Patients with Osteoporotic Hip Fracture in Korea

키워드

참고문헌 (34)

1. Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)
2. Cummings SR, "Epidemiology and outcomes of osteoporotic fractures", Lancet, 359, pp.1761~1767 (2002)
3. Haentjens P, "Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis", J Bone Joint Surg Am, 85, pp.1936~1943 (2003)
4. Salaffi F, "The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study", J Rheumatol, 34, pp.1551~1560 (2007)
5. 윤현구, "Incidence and Mortality Following Hip Fracture in Korea", Journal of Korean Medical Science, 26(8), pp.1087~1092 (2011), 대한의학회
6. Lee YK, "Incidence of second hip fracture and compliant use of bisphosphonate", Osteoporos Int, 24, pp.2099~2104 (2013)
7. Lee YK, "Bisphosphonate use and subsequent hip fracture in South Korea", Osteoporos Int (2013)
8. "Physician’s guide to prevention and treatment of osteoporosis" (2003)[URL]
9. Javid KS, "Implementation of and compliance with NICE guidelines in the secondary prevention of osteoporotic fractures in postmenopausal women", Ann R Coll Surg Engl, 90, pp.213~215 (2008)
10. American Association of Clinical Endocrinologists, "AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis", J Fla Med Assoc, 83, pp.552~566 (1996)
11. 장선미, "골다공증 환자의 의료이용 양상", Endocrinology and Metabolism, 25(4), pp.326~339 (2010), 대한내분비학회
12. 변동원, "Domestic Characteristics and Trends of Publications on Bone Metabolism in South Korea between 1998 and 2012", 대한골대사학회지, 20(1), pp.43~45 (2013), 대한골대사학회
13. Russell RG, "Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy", Osteoporos Int, 19, pp.733~759 (2008)
14. Bilezikian JP., "Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis", Am J Med, 122, pp.S14~S21 (2009)
15. Watts NB., "Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials", Osteoporos Int, 12(Suppl 3), pp.S17~S22 (2001)
16. Boonen S, "Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update", J Intern Med, 259, pp.539~552 (2006)
17. Ensrud KE, "Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial", Arch Intern Med, 157, pp.2617~2624 (1997)
18. Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group", JAMA, 282, pp.1344~1352 (1999)
19. Nowson CA, "Prevention of fractures in older people with calcium and vitamin D", Nutrients, 2, pp.975~984 (2010)
20. Chapuy MC, "Prevention of secondary hyperparathyroidism and hip fracture in elderly women with calcium and vitamin D3 supplements", Osteoporos Int, 6(Suppl 3), pp.60~63 (1996)
21. Lee YK, "Persistence with intravenous zoledronate in elderly patients with osteoporosis", Osteoporos Int, 23, pp.2329~2333 (2012)
22. Choi HJ, "Burden of osteoporosis in adults in Korea: a national health insurance database study", J Bone Miner Metab, 30, pp.54~58 (2012)
23. Lee YK, "Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry", Osteoporos Int, 24, pp.707~711 (2013)
24. Lee YK, "Mortality after vertebral fracture in Korea: analysis of the National Claim Registry", Osteoporos Int, 23, pp.1859~1865 (2012)
25. Gold DT, "A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis", Curr Med Res Opin, 23, pp.585~594 (2007)
26. Siris ES, "Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases", Mayo Clin Proc, 81, pp.1013~1022 (2006)
27. Soong YK, "Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan", Osteoporos Int, 24, pp.511~521 (2013)
28. Stafford RS, "National patterns of calcium use in osteoporosis in the United States", J Reprod Med, 50, pp.885~890 (2005)
29. Norman M, "Compliance with a pharmacological secondary fracture prevention policy", Injury, 37, pp.718~720 (2006)
30. Baek JH, "Knowledge on osteoporosis in guardians of hip fracture patients", J Bone Miner Metab, 31, pp.481~484 (2013)
31. Wilson RK, "Male and non-English-speaking patients with fracture have poorer knowledge of osteoporosis", J Bone Joint Surg Am, 93, pp.766~774 (2011)
32. Nguyen NV, "Awareness and knowledge of osteoporosis in Vietnamese women", Asia Pac J Public Health (2011)
33. Whiting SJ, "Adverse effects of high-calcium diets in humans", Nutr Rev, 55, pp.1~9 (1997)
34. Albertazzi P, "Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial", Climacteric, 7, pp.33~40 (2004)

관련 논문AI추천